Home>Topics>Stocks>Neurocrine Biosciences

Neurocrine Biosciences NBIX

  1. All
  2. Commentary
  3. Headlines
    1. CLS: Slow Down, Think Before You Trade

      Headlines

      Wed, 15 Jan 2014

      On Monday, Neurocrine Biosciences NBIX accelerated its anticipated filing date for indiplon capsules to the second quarter of 2007 instead of 2009. We're placing Neurocrine

    2. Dropping Coverage of Neurocrine

      Commentary

      Mon, 31 Aug 2009

      We are no longer providing equity research on Neurocrine Biosciences NBIX . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.

    3. Neurocrine Searches for Catalyst

      Commentary

      Tue, 16 Jun 2009

      Neurocrine Biosciences NBIX still lacks a compelling late-stage drug candidate. Its indiplon program is dead for now; the company is still waiting on final

    4. Neurocrine under Review

      Commentary

      Thu, 13 Dec 2007

      We're placing Neurocrine Bioscience's NBIX fair value estimate under review following the receipt of its second approvable letter for indiplon. We plan a significant reduction

    5. Neurocrine Resubmits Indiplon

      Commentary

      Wed, 1 Aug 2007

      Neurocrine Biosciences NBIX announced the resubmission of its new drug application for indiplon capsules on July 31. This does not change our fair value estimate

    6. Neurocrine, DOV under Review

      Commentary

      Tue, 23 Jan 2007

      On Monday, Neurocrine Biosciences NBIX accelerated its anticipated filing date for indiplon capsules to the second quarter of 2007 instead of 2009. We're placing Neurocrine

    7. Neurocrine's Delay Will Hurt DOV

      Commentary

      Fri, 3 Nov 2006

      Neurocrine Biosciences NBIX announced Thursday that it is delaying its effective launch date for indiplon to 2010 following discussions with the Food and Drug

    8. Neurocrine's Indiplon Delayed

      Commentary

      Fri, 23 Jun 2006

      Neurocrine Biosciences NBIX and DOV Pharmaceutical DOVP were disappointed Thursday when Pfizer PFE walked away from its agreement to market indiplon for insomnia

    9. Neurocrine's Indiplon Delayed

      Commentary

      Tue, 16 May 2006

      Neurocrine Biosciences NBIX received disappointing news Tuesday regarding its U.S. drug application for indiplon; the Food and Drug Administration (FDA

    10. Neurocrine's Fair Value Raised

      Commentary

      Fri, 15 Jul 2005

      previously estimated, we are raising our forecast for Indiplon sales and raising our fair value estimate on Neurocrine Biosciences NBIX to $44 per share from $34. We reviewed the prescription drug trends for insomnia medications for April

    Content Partners